CLAIMS

1. A maleate salt of AZD2171.

2. A maleate salt of AZD2171, according to claim 1, in the crystalline form, Form A.

3. A maleate salt of AZD2171, according to claim 1, in the crystalline form, Form B.

4. A maleate salt of AZD2171, according to claim 2, in the crystalline form, Form A, wherein said salt has an X-ray powder diffraction pattern with at least one specific peak at about 2-theta = 21.5°.

5. A maleate salt of AZD2171, according to claim 2, in the crystalline form, Form A, wherein said salt has an X-ray powder diffraction pattern with at least one specific peak at about 2-theta = 16.4°.

6. A maleate salt of AZD2171, according to claim 2, in the crystalline form, Form A, wherein said salt has an X-ray powder diffraction pattern with at least two specific peaks at about 2-theta = 21.5 and 16.4°.

7. A maleate salt of AZD2171, according to claim 2, in the crystalline form, Form A, wherein said salt has an X-ray powder diffraction pattern with specific peaks at about 2-theta = 21.5, 16.4, 24.4, 20.7, 25.0, 16.9, 12.1, 22.2, 17.4 and 17.6°.

8. A maleate salt of AZD2171, according to claim 2, in the crystalline form, Form A, wherein said salt has an X-ray powder diffraction pattern substantially the same as the X-ray powder diffraction pattern shown in Figure 5.

9. A maleate salt of AZD2171, according to claim 3, in the crystalline form, Form B, wherein said salt has an X-ray powder diffraction pattern with at least one specific peak at about 2-theta = 24.2°.

10. A maleate salt of AZD2171, according to claim 3, in the crystalline form, Form B, wherein said salt has an X-ray powder diffraction pattern with at least one specific peak at about 2-theta = 22.7°.

11. A maleate salt of AZD2171, according to claim 3, in the crystalline form, Form B, wherein said salt has an X-ray powder diffraction pattern with at least two specific peaks at about 2-theta = 24.2 and 22.7°.

12. A maleate salt of AZD2171, according to claim 3, in the crystalline form, Form B, wherein said salt has an X-ray powder diffraction pattern with specific peaks at about 2-theta = 24.2, 22.7, 15.7, 12.0, 27.1, 25.0, 17.7, 15.0, 23.1 and 12.6°.

13. A maleate salt of AZD2171, according to claim 3, in the crystalline form, Form B, wherein said salt has an X-ray powder diffraction pattern substantially the same as the X-ray powder diffraction pattern shown in Figure 8.

14. A pharmaceutical composition which comprises a maleate salt of AZD2171 according to claim 1 in association with a pharmaceutically acceptable excipient or carrier.

15. A pharmaceutical composition according to claim 14 wherein the AZD2171 maleate salt is in the crystalline form, Form A.

16. A pharmaceutical composition according to claim 14 wherein the AZD2171 maleate salt is in the crystalline form, Form B.

17. A process for the preparation of a maleate salt of AZD2171 in the crystalline form Form A, as claimed in claim 2, which comprises:

(i) dissolving AZD2171 free base in an organic solvent to form a solution;
(ii) adding an aqueous solution of maleic acid or adding a solution of maleic acid in an organic solvent;
(iii) allowing spontaneous nucleation to occur;
(iv) slurrying the mixture in a solvent until all the AZD2171 maleate is Form A; and
(v) isolating the crystalline solid so formed.

18. A process for the preparation of a maleate salt of AZD2171 in the crystalline form Form A, as claimed in claim 2, which comprises:

(i) dissolving AZD2171 free base in an organic solvent to form a solution;

(ii) adding an aqueous solution of maleic acid or adding a solution of maleic acid in an organic solvent;

(iii) obtaining a solution and adding a seed of AZD2171 maleate Form A to initiate crystallisation of AZD2171 maleate Form A; and

(iv) isolating the crystalline solid so formed.

19. A process for the preparation of a maleate salt of AZD2171 in the crystalline form Form B, as claimed in claim 3, which comprises:

(i) dissolving AZD2171 maleate in an organic solvent to form a solution;

(ii) adding the solution to a solvent in which AZD2171 maleate has a lower solubility than it does in NMP;

(iii) crystallisation of AZD2171 maleate Form B then occurs; and

(iv) isolating the crystalline solid so formed.

20. Use of a maleate salt of AZD2171 as claimed in claim 1 in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human being.

21. A method for producing an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal, such as a human being, in need of such treatment which comprises administering to said animal an effective amount of an AZD2171 maleate salt as claimed in claim 1.